'50 mg bid' diaporamas de présentation

Oncology Journal Club Addressing Imatinib-resistant CML

Oncology Journal Club Addressing Imatinib-resistant CML. Frank Giles, MD, FRCPI, FRCPath Chief, Division of Hematology and Medical Oncology Director, Institute for Drug Development Deputy Director, CTRC at University of Texas Health Science Center San Antonio, TX.

964 views • 63 slides

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

492 views • 22 slides

(and circ.ahajournals r23-r35).

A Phase 3 International, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety Of O rbofiban in P atients with U nstable Coronary S yndromes. (and www.circ.ahajournals.org r23-r35). Cannon CP et al. Circulation 2000;102:149-156.

310 views • 21 slides